Nohla Therapeutics

Nohla Therapeutics

Nohla Therapeutics

Nohla is the leading developer of universal donor cell therapies for patients with hematologic malignances and other critical diseases.
Raised
$99.5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$11,000,000
Venture capital (Series B) - 2018
University of Tokyo Edge Capital Premier Partners Schroder Adveq
$45,000,000
Venture capital (Series B) - 2018
ARCH Venture Partners 5AM Ventures Fidelity Management +4
Team Size
1–10
Employees
GeekWire

Tech Moves: Nohla Therapeutics hires chief medical officer; Apptio adds to board; and more

Strategy Funding
$11,000,000 Venture capital (Series B)
FinSMEs , GeekWire

Nohla Therapeutics Raises Additional $11M in Second Close of $56M Series B

Funding Health
$45,000,000 Venture capital (Series B)
FinSMEs

Nohla Therapeutics Closes $45M Series B Financing

Health Funding
GeekWire

Nohla Therapeutics raises $45M, gets new HQ as it moves novel leukemia treatment closer to market

Health Funding
GeekWire

Inside Nohla Therapeutics’ new Seattle biotech lab as Gov. Jay Inslee geeks out on science

Science
$43,500,000 Venture capital (Series A)
GeekWire

Fred Hutch spinout Nohla Therapeutics raises $43.5M to develop therapy for Leukemia

Health Funding